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A bstract
T h e p res e n t s tu d y w a s c arrie d o u t to e x am in e
the m echanism s o f the synergistic in teraction o f
P A F a n d A 2 3 18 7 m e d ia ted p la tele t a g g reg atio n .
W e fo u n d th at p la telet a g g re g atio n m ed iate d b y
su b th re sh o ld co n ce n tratio n s o f P A F (5 n M ) an d
A 2 3 18 7 (1 µM ) w as in h ib ite d b y P A F re ce p to r
b lo ck e r (W E B 2 08 6 , IC 50 = 0 .65 µM ) a n d c a lciu m
c h a n n e l b lo c ke rs , d iltiazem (IC 50 = 13 µM ) a n d
v era p a m il (IC 50 = 18 µM ). P retre atm e n t o f p la te le ts w ith P A F an d A 2 31 8 7 in d u c ed ris e in in trac e llu la r ca lc iu m an d th is e ffe c t w a s a ls o
b lo c ke d b y v era p am il. W h ile e xa m in in g th e ro le
o f th e d o w n stre am sig n a lin g p a th w ay s , w e
fo u n d th at p late let ag g re g a tio n in d u c e d b y th e
c o -ad d itio n o f P A F an d A 2 31 8 7 w a s a ls o in h ib ited b y lo w co n cen tratio n s o f p h o sp h o lip ase C
(P L C ) in h ib ito r (U 7 3 12 2 ; IC 50 = 1 0 µM ), a c yc lo oxygenase inhibitor (indom ethacin; IC 50 = 0.2 µM )
a n d in h ib ito r o f T L C K , h erb im yc in A w ith IC 50
v alu e o f 5 µM . T h e e ffec t w as als o in h ib ite d b y
a sp ec ific T X A 2 rec e p to r a n tag o n is t, S Q 29 5 48
w ith v e ry lo w IC 50 va lu e o f 0 .0 5 µM . H o w e v er,
the inhibitors of M A P kinase, PD 98059 and pro tein kinase C, chelerythrine had no effect on PAF
and A 2 31 8 7-in d u c ed p la te le t a g g reg atio n . T h e s e
d a ta s u g g e st th a t th e s yn erg ism b etw e en P A F
and A23187 in platelet aggregation involves activation of throm boxane and tyrosine kinase pathways.
K eyw ords: calcium ionophore A23187; platelet activat-

In tro d u c tio n
A number of platelet agonists such as epinephrine,
5-HT, ADP, and platelet activating factor (PAF) act
synergistically in platelet aggregation and up to date,
few studies have been carried out in human platelets
on the cooperative effects of PAF and calcium ionophore A23187. It is well documented that most of
the platelet agonists act largely through the stimulation of G-protein coupled receptors (GPCRs).
PAF, a phospholipid mediator, is a very strong
platelet activator and human platelets show high
affinity binding sites for this agonist. It also induces
adhesion of platelets to the endothelium in the presence of activated leukocytes (Hirafuji and Shinoda,
1991). PAF is also known to play an important role
in various pathophysiological conditions that include
modulation of blood pressure, hypotension, cardiac
dysfunction, cardiac anaphylaxis, hemorrhagic, traumatic and septic shock syndromes (Anderson et al.,
1991; Montrucchio et al., 2000). Because of its ability
to stimulate endothelial migration and angiogenesis,
a potential role of PAF is also known as a potent
stimulator of thromboxane A 2 (TXA 2 ) production in
human platelets (Shah et al., 2001). It is reported that
PAF acts through the stimulation of pertussis toxin
insensitive G-proteins (Gq/11) resulting in the stimulation of phospholipase C (PLC) and thus generation
of second messenger diacylglycerol (DAG) and inositol-1, 4,5-triphosphate (IP 3 ), which results in the
activation of protein kinase C (PKC) and the mobili2+
zation of intracellular Ca , respectively (Obberghen2+
Schilling and Pouyssegur, 1993). Both Ca and PKC
stimulate platelet aggregation and also elicit synergism in platelets (Crabos et al., 1992). Consistent with
the potential involvement of G q /PLC pathway, the
deficiency of G q protein in transgenic mice leads to
impairment of agonist-induced platelet aggregation
(Offermanns et al., 1997).
In platelets, calcium plays a pivotal role in platelet
aggregation (Heemskerk and Sage, 1994). An increase in cytoplasmic Ca 2+ can be brought about by
either enhanced Ca 2+ influx from the external medium
or release from internal stores (Berridge, 1993). Ca 2+
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ionophores, such as A23187, induce platelet aggregation. It stimulates the procoagulant activity of cells,
which is thought to be mediated by scrambling of the
plasma membrane phospholipids. This results in the
exposure of phosphatidyl inositol serine and other
negatively charged phospholipids in the outer leaflet
of the plasma membrane (W illiamson et al., 1995).
In addition, PAF also stimulates TXA 2 production
in human platelets. It enhances vasoconstriction of
the coronary arterioles (DeFily et al., 1996) and at
the inflammatory coronary lesions in vivo by itself as
well as in a synergistic manner with other agonists
like epinephrine and 5-HT (Shah et al., 2000; Saeed
and Rasheed, 2003). Because of the close interaction
between many agonists and their importance in
thrombosis, hypertension and atheroscelrosis, this
study was conducted to examine the synergism between PAF and A23187 to elucidate the possible signaling mechanism(s) involved during this synergism.

M a terials a n d M eth o d s
C hem icals
PAF, calcium ionophore, A23187, diltiazem, verapamil, herbimycin A, U73122, PD98059 and chelerythrine all were purchased from the Sigma Chemical
Co. (St. Louis, Mo). All other chemicals used were
of the highest purity grade available.
Preparation of hum an platelets
Blood was taken by vein-puncture from normal human
volunteers reported to be free of medications for one
week. Blood samples were mixed with 3.8% (w/v)
sodium citrate solution (9:1) and centrifuged at 260
g for 15 min at 20 o C to obtain platelet rich plasma
(PRP). Platelet count was determined by phase contrast microscopy and all aggregation studies were
o
carried out at 37 C with PRP having platelet counts
8
-1
between 2.5 and 3.0×10 ml of plasma (Shah and
Saeed, 1995).
M easurem ent of platelet aggregation
Aggregation was monitored using Dual-channel Lumiaggregometer (Model 400 Chronolog Corporation,
Chicago, IL) using 0.45 ml aliquots of PRP. The final
volume was made up to 0.5 ml with the test drug
dissolved either in normal saline or appropriate vehicle known to be devoid of any effect on aggregation. Aggregation was induced with PAF and A23187
and their sub-threshold concentrations were determined. To obtain the synergistic effect of PAF and
A23187, we added low concentrations of these
agonists. The anti-aggregatory effects of different
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compounds were studied by pretreatment of PRP with
various inhibitors for one min followed by addition of
the sub-threshold concentrations of PAF (5 nM) and
A23187 (1 µM). The resulting aggregation was recorded for 5 min after challenge by the change in
light transmission as a function of time. Once the
anti-platelet activity of various inhibitors against these
agonists was established, dose-response curves were
constructed to calculate the IC 50 values of inhibitors.

Throm boxane form ation in platelets
Arachidonic acid metabolism and TXA 2 formation were
studied with the co-addition of PAF (5 nM) and
A23187 (1 µM) using radiochemical methods (Shah
et al., 2000). For these studies, human blood platelets
were routinely obtained in plastic bags containing
30-40 ml of concentrated PRP from The Aga Khan
University Hospital Clinical Laboratory, Karachi. The
PRP was centrifuged at 1,200 g for 20 min and the
sedimented platelets were washed twice with an
ice-cold phosphate buffer (50 mM, pH 7.4) containing
sodium chloride (0.15 M) and EDTA (0.2 mM). After
centrifugation, washed platelets were resuspended in
the same buffer without EDTA and homogenized at
o
4 C using a polytron homogenizer for 15 s. The
homogenate was centrifuged at 1,200 g for 20 min
and 300 µl of the supernatant (containing 0.4 mg of
protein) was incubated with 10 µg unlabelled ara14
chidonic acid (AA) and 0.1 µCi [1- C]-arachidonic
acid in the presence and absence of the agonists.
After 15 min of gentle shaking in air at 37 o C, the
reaction was stopped by adding 0.4 ml of citric acid
(0.4 M) and ethyl acetate (7.0 ml). After mixing and
centrifuging at 600 g for 5 min at 4 o C, the organic
layer was separated and evaporated to dryness under
nitrogen. Residues were dissolved in 40 µl ethanol
and 20 µl were applied to silica gel G thin layer
chromatography (TLC) plates (Analtech, Delaware).
The solvent system used for the separation of TXB 2
in dried organic extracts of platelet incubates as
above was ethyl acetate: isooctane: water and acetic
acid (11:5:10:2, v/v, upper phase). Radioactive zones
were located and quantified by use of a Berthold
T.L.C. linear analyzer and chromatography data system (Model LKB 511, Berthold, W. Germany). Protein
concentration was determined using human serum
albumin as standard (Lowry et al., 1951).
M easurem ent of C a 2+ Influx
The agonist-induced influx of Ca 2+ was measured
using Fura-2 AM (Saeed et al., 1997). Platelets (1×
10 8 /m l) w ere suspended in C a 2+ -free standard
medium (NaCl 145 mM, KCl 5 mM/L, MgCl2 1 mM/L,
HEPES 10 mM, glucose 10 mM, pH 7.4). Fura-2 AM
dissolved in DMSO was added to the platelet sus-
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pension at 37 o C for 45 min. The platelet suspension
was centrifuged at 350 g for 15 min and the platelet
pellet resuspended in fresh standard medium. Fura2AM fluorescence was monitored at 340 nm and 505
nm (excitation and emission, respectively) in platelets
treated with PAF (5 nM) and A23187 (1 µM).

R e su lts
The results demonstrated that treatment of PRP with
PAF (5-800 nM) and A23187 (1 µM) showed concentration-dependent increase in platelet aggregation.
However, simultaneous addition of subthreshold concentrations of PAF (5 nM) and A23187 (1 µM) exhibited a synergistic effect (Figure 1A). Such an effect
was comparable to that obtained by higher concentrations of PAF (800 nM) or A23187 (10 µM)
alone. The synergism between PAF and A23187 was
inhibited by pre-treatment of PRP with a potent PAF
antagonist, W EB 2086 (IC 50 = 0.65 µM) (Figure 1B)

Aggregation (%)

Table 1. The effect of various inhibitors on subthreshold concentration
of platelet activating factor (5 nM) and A23187 (1 µM) induced platelet
aggregation.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Inhibitors
Mean IC 50 µM ± SEM
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
W EB 2086
0.65 ± 0.04
Diltiazem
13 ± 2.3
Verapam il
18 ± 3.2
U73122
10 ± 0.7
Indom ethacin
0.2 ± 0.03
SQ 29548
0.05 ± 0.001
Herbim ycin A
5 ± 0.8
PD98056
NE
Chelerythrine
NE
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Data is mean ± SEM (n = 5-7) and is indicated as half-maximal effect
(IC 50 ) of the inhibitors. NE, No effect.

D ata analysis
IC 50 is the concentration (µM) producing 50% inhibition of platelet aggregation (control response taken
as 100%). The 50% inhibitory concentration (IC 50 )
values were calculated as means ± SEM of 5-7
independent experiments. Differences between control
and test measurements were assessed by student's
t-test.
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Figure 1. (A) Tracings from representative experiments showing synergism of PAF (5 nM) and A23187 (1 µM). The synergistic
effect of PAF and A23187 on platelet aggregation is blocked by (B) W EB 2086, a PAF receptor antagonist, (C) U73122, a
phospholipase C inhibitor and (D) diltiazem, a calcium channel blocker. Inhibitors were added one minute before the agonists.
Control means platelet aggregation induced by PAF (5 nM) and A23187 (1 µM). n = 5.
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Figure 2. Effect of verapamil on PAF (5 nM) and A23187 (1 µM)
2+
induced rise in intracellular calcium [Ca ]. Platelets were loaded with
Fura-2 AM and assays done as described in Materials and Methods.
Control represents unstimulated platelets and is taken as 100%. n =
6. Mean ± SEM.

TXA2 formation

0

Figure 4. Effects of subthershold concentrations of PAF and A23187
on thromboxane A 2 (TXA 2 ) formation in human platelets. n = 6.

indicating that the effect is receptor mediated. W e
used PLC inhibitor; U73122 to examine if PAF and
A23187 mediated effects involved the activation of
PLC. Results show that pretreatment of PRP with
U73122 completely inhibited the synergistic effect of
PAF and A23187 with an IC 50 of 10 µM (Figure 1C).
W e also tested the effect of Ca 2+ channel blockers
on platelet aggregation and found that the synergistic
effect of PAF and A23187 was inhibited by both
verapamil and diltiazem (Figure 1D) with IC 50 values
of 18 and 13 µM respectively.
Similar inhibitory effect of verapamil was also obtained using Fura-2 AM assay for the measurement
of Ca 2+ release as shown in Figure 2. To determine
the role of cyclooxygenase, we used indomethacin
(Figure 3A) which inhibited PAF and A23187 induced
aggregation with IC 50 value of 0.2 µM while, SQ
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Figure 3. (A) Concentration-dependent effects of cyclooxygenase
inhibitor, indomethacin and (B) TXA 2 receptor antagonist, SQ 29,548
on platelet aggregation induced by co-addition of PAF and A23187.
Control means platelet aggregation induced by PAF (5 nM) and
A23187 (1 µM). n = 7.

29548 a specific TXA 2 receptor antagonist also inhibited platelet aggregation with IC 50 value of 0.05 µM
(Figure 3B). Both PAF and A23187 in subthreshold
concentrations also stimulated TXA 2 formation in
platelets up to many folds (Figure 4). The results of
SQ, 29548 and TXA 2 stimulation clearly explain the
involvement of thromboxane/COX pathway in PAF
and A23187 induced platelet aggregation.
Herbimycin A, a specific inhibitor of tyrosine kinase
also inhibited PAF and A23187-induced aggregation
with IC 50 of 5 µM indicating the involvement of tyrosine kinase in this cascade (Figure 5).
2+
As stimulation of the G-protein/Ca cascade leads
to mitogen activated protein (MAP) kinase signaling
(Heemskerk and Sage, 1994), we used the selective
MEK inhibitor PD98059 against PAF and A23187
synergism. Results show that pretreatment of PRP
with PD98059 did not show any inhibitory effect on
platelet aggregation by co-addition of subthreshold
concentration of PAF and A23187. Similarly, the
inhibitor of protein kinase C (chelerythrine; 20 µM)
had no effect.
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Figure 5. Dose-response curve of specific tyrosine kinase inhibitor,
herbimycin A on the synergistic interaction of subthreshold concentrations of PAF and A23187. n = 7

D iscu s sio n
In human platelets PAF causes the stimulation of Gq
proteins by binding with specific transmembrane PAF
2+
receptors. The second messengers, Ca and PKC
generated in response to Gq/PLC activation bring
about coordinated changes leading towards platelet
aggregation (Crabos et al., 1992; Heemskerk and
2+
Sage, 1994). This indicates that both PAF and Ca
play a pivotal role in aggregation. Similarly our study
shows that both PAF and A23187 in subthershold
concentrations show synergism when used exogenously. While studying mechanism of PAF and A23187
mediated aggregation we found that different inhibitors exhibited variable response against the synergism.
Our data show that W EB2086, a PAF receptor
antagonist inhibited PAF and A23187 induced aggregation at very low IC 50 values showing that the effect
is receptor mediated.
PAF causes the stimulation of Gq protein followed
by the activation of PLC. This explains why U73122,
a selective inhibitor of PLC, shows strong inhibitory
effects as platelet aggregation induced by co-activation of these agonists. Further support in favour of
Gq/PLC pathways is provided by the recent studies
in transgenic mice where it is shown that Gq protein
deficient mice lacked the ability of platelet aggregation
(Offermanns et al., 1997). Some of the investigators
reported that platelets lack L-type voltage dependent
calcium channels but contain receptors operated
calcium channels. The antiplatelet effects of calcium
antagonists have been extensively studied in vitro, but
such studies may involve high concentrations of the
drugs. Verapamil is well-documented calcium antagonist with regard to antiplatelet effects having the
most varied possible mechanisms of action (Hjemdahl
and W allen, 1997). Our previous studies show that
synergistic effect of various platelet agonists is

blocked by calcium-channel blockers, verapamil and
diltiazem in very low concentration (Saeed et al.,
1997; Shah et al., 1999; Saeed et al., 2003). Similarly
the present findings also show that PAF and A23187
mediated platelet aggregation is also blocked by low
concentration of verapamil or diltiazem. It is also
supported by other studies that calcium channel
blockers inhibit platelet activation induced by various
agonists through different intracellular mechanisms
(Valone, 1987).
Results with the channel blockers are consistent
with the enduring proposal that calcium influx causes
aggregation (Ware et al., 1986; Vinge et al., 1988).
The increase in cytosolic Ca 2+ causes activation of
PLA 2 and stimulation of COX activity, thus TXA 2
formation (Heemskerk and Sage, 1994).
COX catalyzes the stepwise conversion of AA into
reactive intermediates PGG 2 and PGH 2, which are the
precursors of prostaglandins, prostacyclin and thromboxanes (prostanoids). COX-1 is mainly present in
platelets and in other tissues (Piomelli, 1993). Numerous studies have shown that inhibitors of COX
mainly belonging to the group of non-steroidal antiinflammatory drugs (NSAIDs) also inhibit platelet
aggregation by inhibiting TXA 2 biosynthesis. TXA 2 in
an antocrine fashion binds with TXA 2 receptors
coupled with Gq protein and stimulate PLC and
further enhance platelet aggregation. MAP kinase is
one of the down stream signaling molecules involved
in platelet aggregation (Shah et al., 2000). That can
cultivate both Gq and Gi-protein linked pathways
(Della Rocca, et al., 1999).
Many studies show that activation of platelets by
some agonists increase the level of tyrosine phosphorylation resulting in the appearance of a new set
of tyrosine-phosphorylated proteins (Ferrel and Martin,
1988; Golden and Yamamura, 1989). Increase in the
phosphorylation of tyrosine residues is an early event
in the signal transduction pathway for stimulation of
platelets by PAF (Animesh et al., 1990). To investigate the involvement of tyrosine kinase in present
study we used herbimycin A, a known and specific
inhibitor of tyrosine kinase which block PAF and
A23187-induced aggregation in a concentration- dependent manner (IC 50 = 15 µM) showing that the
synergism may also be due to the TLCK activation.
W e found that MAPK inhibitor; PD98059 did not
exhibit any inhibitory effect showing that MAP kinase
pathway was inactive in PAF and A23187 mediated
aggregation. However the role of PKC in the present
study was changed as PKC inhibition had no effect
on the synergism of PAF and A23187 in platelets In
conclusion, our study show that the synergistic interaction of PAF and A23187 in human platelet
aggregation seems to follow the activation of thromboxane and tyrosine kinase pathways.

Pathways in PAF and A23187 mediated platelet aggregation
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